Siemens Healthineers AG. (12/10/24). "Press Release: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging".

	Organisation	Siemens Healthineers AG (Frankfurt: SHL)
	Group	Siemens (Group)
	Organisation 2	Advanced Accelerator Applications S.A. (Nasdaq: AAAP)
	Group	Novartis (Group)
	Product	RADIOPHARMACEUTICAL (RPT)
	Product 2	positron emission tomography (PET)
	Person	Williams, James (Siemens 201304 CEO of Siemens Molecular Imaging business unit)

> Molecular Imaging business acquired from Novartis

> Deal extends our network of PET radiopharmaceuticals production sites across Europe

> Provides support for patients with cancer, heart disease and neurological disorders

Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.

The acquisition complements the Siemens Healthineers PETNET Solutions network of 47 PET radiopharmacies, primarily in the U.S., with an additional 13 manufacturing sites across France, Spain, Portugal, Italy, and Germany, as well as product distribution into Switzerland. Proximity to patients is essential for PET radiopharmaceuticals, with short half-lives. PETNET Solutions also manufactures diagnostic agents used for an innovative form of personalized cancer treatment.

“The radiopharmaceutical sector is at an inflection point thanks in large part to innovation in the pharmaceuticals space, with PET serving as a gateway to patient eligibility for many of the new cancer and neurodegenerative-disorder therapies,” said Jim Williams, head of Molecular Imaging at Siemens Healthineers. “But even the greatest therapy is of no use unless you can get it to patients in time, so we’re excited to be adding the molecular imaging capabilities of Advanced Accelerator Applications, its first-class operations, extensive experience in nuclear medicine, and proven track record.”

The transaction includes the manufacturing and distribution network of Advanced Accelerator Applications Molecular Imaging, its workforce of approximately 420, its established product portfolio and relationships with radioligand imaging developers.

“We’re delighted to welcome our new colleagues to Siemens Healthineers and start our collaboration at this time of unprecedented growth in our industry,” said Barry Scott, CEO of PETNET Solutions.

The PET radiodiagnostics sector, serviceable from the countries listed above and the PETNET Solutions UK facilities, is currently worth around €500 million ($538 million) annually and is expected to triple by 2033, driven by the development of innovative tracers. Key growth drivers include third-party tracers for oncology, neurology, and cardiology.

About PETNET Solutions

PETNET Solutions is a segment of the Siemens Healthineers Molecular Imaging business, supplying positron emission tomography (PET) radiopharmaceuticals globally. PETNET currently operates 47 cyclotron-equipped radiopharmacies and delivers nearly 1.6 million patient doses to more than 2,800 imaging centers each year. PETNET also operates as a contract development and manufacturing organization for multiple IP holders and provides related services.
Image Gallery

Radiopharmacies are specifically designed to handle radioactive materials safely.

Proximity to patients is essential for PET radiopharmaceuticals due to their short half-lives.

Contact

Julie Gibson
Head of US Corporate Press

Jeffrey T. Bell
Molecular Imaging and Imaging (USA)

Georgina Prodhan
Head of Media Relations, Financials and International

Siemens Healthineers 2025

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.

Record changed: 2024-12-19